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Abstract: Inflammation is involved in the pathogenesis of several age-related ocular diseases, such as
macular degeneration (AMD), diabetic retinopathy, and glaucoma. The delivery of anti-inflammatory
siRNA to the retinal pigment epithelium (RPE) may become a promising therapeutic option for
the treatment of inflammation, if the efficient delivery of siRNA to target cells is accomplished.
Unfortunately, so far, the siRNA delivery system selection performed in dividing RPE cells in vitro has
been a poor predictor of the in vivo efficacy. Our study evaluates the silencing efficiency of polyplexes,
lipoplexes, and lipidoid-siRNA complexes in dividing RPE cells as well as in physiologically
relevant RPE cell models. We find that RPE cell differentiation alters their endocytic activity and
causes a decrease in the uptake of siRNA complexes. In addition, we determine that melanosomal
sequestration is another significant and previously unexplored barrier to gene silencing in pigmented
cells. In summary, this study highlights the importance of choosing a physiologically relevant RPE
cell model for the selection of siRNA delivery systems. Such cell models are expected to enable the
identification of carriers with a high probability of success in vivo, and thus propel the development
of siRNA therapeutics for ocular disease.
Keywords: siRNA delivery; polyplex; lipoplex; lipidoid; retinal pigment epithelium; physiologically
relevant RPE cell model; melanin; melanosome
1. Introduction
Age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma are common
age-related eye conditions and major causes of visual impairment and blindness. According to the
World Health Organization, the number of people affected by AMD and glaucoma will increase from
195.6 million in 2020 to 243.4 million in 2030 due to a variety of factors such as ageing population,
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lifestyle, and noncommunicable diseases (WHO world report on vision). Although the underlying
mechanisms responsible for the pathogenesis of AMD have not been fully elucidated, the presence
of inflammatory cells in the ocular tissues of AMD patients had been recognized already in the
1980s [1,2]. Considerable evidence now supports the central role of chronic low-level inflammation
(para-inflammation) in the pathogenesis of several human diseases [3], including age-related eye
disorders such as AMD [4–7], diabetic retinopathy [8–11], and glaucoma [12].
AMD is triggered by the degeneration of the retinal pigment epithelium (RPE), a highly specialized
monolayer of pigmented, terminally differentiated, post-mitotic cells joined apically with tight junctions
that form the outer blood-retina barrier (BRB) [13]. This barrier regulates the traffic of cells and molecules
between the blood and the neural retina, and it thus plays a crucial role in maintaining the viability of
the retina. The RPE exerts several essential supportive functions of homeostasis, including the daily
phagocytosis of photoreceptor outer segments, light absorption to optimize vision and protect from
photo-oxidative damage, the upkeep of the visual cycle, and the secretion of growth factors essential
for the maintenance of the retina and the choriocapillaris [14]. The RPE also plays an essential role
in modulating the immune-regulatory environment of the eye by protecting it from an exaggerated
immune response that may cause harmful chronic inflammation and a variety of pathologic processes.
RPE dysfunction can negatively affect the retina in two ways; first, it may lead to the breakdown of
the BRB and to the consequent loss of the immune privilege of the eye. Second, the RPE can also
contribute to the establishment of a proinflammatory environment in the neural retina by secreting a
variety of inflammatory cytokines, chemokines, and growth factors [15,16]. A therapeutic strategy
that silences the proinflammatory genes in the RPE may thus alleviate the inflammation and restore
retinal homeostasis.
Gene silencing can be achieved with small interfering RNA (siRNA). siRNA is a powerful tool,
whose selective and sequence-specific gene knockdown has been demonstrated in a variety of tissues
in vitro and in vivo [17,18] and, in 2018, it has led to the approval of the first siRNA, patisiran, for the
treatment of polyneuropathy in patients with hereditary transthyretin amyloidosis [19]. The eye is
an ideal target organ for siRNA therapeutics because, given its immune privileged and enclosed
properties, it enables a local therapy, thus minimizing the likelihood of systemic toxicity. Despite
these advantages, the delivery of siRNA to the posterior segment of the eye, and to the RPE in
particular, is not trivial for several reasons. Naked siRNA is prone to nuclease degradation, and it is
too large, hydrophilic, and negatively charged to overcome the barriers present in the eye. In addition,
siRNA can also stimulate the immune system through the Toll-like receptor pathway [20,21]. These
disadvantages can be overcome, to some extent, by incorporating the siRNA into a carrier, leading
to the formation of siRNA/carrier complexes. The suitability of a certain carrier varies depending
on the tissue, thus careful in vitro testing in physiologically relevant tissue models is required to
select the optimal siRNA delivery system for the tissue of interest. In the case of the RPE, various
carriers have been evaluated for their siRNA knockdown efficacy in vitro [22–26]; unfortunately, these
studies have been performed using dividing cells that do not appropriately represent the terminally
differentiated, post-mitotic RPE found in vivo [27]. For example, our recent study [28] has shown
that the promising knockdown levels obtained with dividing RPE cells did not translate to adequate
efficacy in differentiated cells. Similar trends have also been observed with the transfection efficiency
of plasmid DNA in several cell lines [29–31].
This study examines the suitability of a polymer carrier (poly(benzyl-l-glutamate) and poly-l-
lysine), a lipid carrier (1,2-Dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), and protamine sulfate (PS) liposomes), a lipidoid carrier (1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG), cholesterol,
lipidoid), and a few commercial carriers as siRNA delivery vehicles. The knockdown efficacy is
evaluated at the mRNA and at protein level in relevant RPE cell models (human ARPE-19 cell line,
primary porcine RPE, and human embryonic stem cell-derived RPE), at different maturation stages.
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The effect of cell differentiation, including the role of melanin, on the siRNA knockdown efficiency
is assessed.
2. Materials and Methods
2.1. Materials
Chloroform (CH2Cl2), methanol (MeOH), ammonium hydroxide (NH4OH), spermidine, 1,2-
epoxytetradecane (ETD), 2-(N-morpholino)ethanesulfonic acid (MES), 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES), protamine sulfate (PS), chloroform, collagen IV from human
placenta, GAPDH siRNA (SS: 5′-GGUCAUCCAUGACAACUUU[dT][dT]-3′, AS: 5′-AAAGUUGUCA
UGGAUGACC[dT][dT]-3′), HPRT1 siRNA (SS: 5′-CCAGUAAAGUUAUCACAUGUUCUdAdG-3′,
AS:5′-CUAGAACAUGmUGmAUAACUUUmACmUGmGmUmG-3′), control siRNA (SS: 5′-UU
CUCCGAACGUGUCACGUTT-3′, AS: 5′-ACGUGACACGUUCGGAGAATT-3′), unlabeled DNA
strand (5′-ACTTGTGGCCGTTTACGTCGC-3′), human GAPDH primers (F: 5′-GTCAGCCGCATC
TTCTTTTG-3′, R: 5′-GCGCCCAATACGACCAAATC-3′), human β-actin primers (F: 5′-AGAG
CTACGAGCTGCCTGAC-3′, R: 5′-AGCACTGTGTTGGCGTACAG-3′), porcine HPRT1 primers
(F: 5′-GGTCAAGCAGCATAA-3′, R: 5′-GGCATAGCCTACCAC-3′), and porcine GAPDH primers
(F: 5′-GATCATCAGCAATGCCTCCT-3′, R: 5′-TGTGGTCATGAGTCCTTCCA-3′) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The matrigel growth factor reduced (GFR) basement membrane
matrix was from Corning Inc. (Corning, NY, USA). IL-6 siRNA (SS: 5′-GAACGAAUUGACAAA
CAAAtt-3′, AS: 5′-UUUGUUUGUCAAUUCGUUCgt-3′), carboxyfluorescein-labeled IL-6 siRNA
(FAM-IL-6 siRNA) with the same sequence, and Atto565-labeled DNA strand (5′-Atto565-
GACGTAAACGGCCACAAGTTC-3′) were purchased from Eurofins Genomics (Ebersberg, Germany).
Nuclease-free water, Alexa Fluor 488 TFP ester, and all the cell culture reagents (unless stated
otherwise) were from Thermo Fisher Scientific (Walthan, MA, USA). 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG), 1,2-Dioleoyl-3-trime
thylammoniumpropane (DOTAP), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were
from Avanti Polar Lipids (Alabaster, AL, USA). The lipids were used without further purification.
The extruder was also from Avanti Polar Lipids and the 100 nm Nuclepore® polycarbonate membranes
(diameter 19 mm) were from Whatman Int. Ltd. (Maidstone, UK).
2.2. siRNA Delivery Systems
2.2.1. Polyplexes
Cationic micelles were prepared by dissolving the amphiphilic polypeptide block copolymer
PBE30-b-PK30 [32] in nuclease-free water at a stock concentration of 1 mg/mL. Then, the siRNA and the
micellar solution were both diluted in 10 mM HEPES (pH 7.2), mixed together, and incubated at room
temperature for at least 20 min to form polyplexes. The used charge ratio (N/P) was 8/1. The charge
ratio was the molar ratio of positive/negative charges originating from the amines of the carrier and
the phosphate of the siRNA strand, respectively (N/P).
2.2.2. Lipoplexes
Cationic liposomes composed of DOTAP and DOPE were prepared by the thin lipid hydration
method described by Ruponen et al. [33]. Shortly, the lipids were mixed at a molar ratio of 1:1 (3.2 mM)
in chloroform. The organic solvent was evaporated to obtain a lipid film, which was hydrated in
nuclease-free water at +30 ◦C for 30 min. After 2 h at room temperature, the liposome solution was
sonicated for 5 min at +30 ◦C and extruded several times through a 100 nm polycarbonate membrane.
The cationic liposomes were stored at +4 ◦C and used within three months of preparation.
The DOTAP/DOPE/PS-siRNA lipoplexes were prepared by mixing 4.7 µg of siRNA with 10 µg of
protamine sulfate solution in MES-HEPES (pH 7.2). After 10 min of incubation, the DOTAP/DOPE
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liposomes were added. The lipoplexes were incubated for 20 min. The charge ratio (N/P) of the formed
lipoplexes was 4.5/1 [34].
2.2.3. Lipidoid-siRNA Complexes
Lipid-like molecules (lipidoid) were synthesized by a ring-opening reaction between
1,2-epoxytetradecane (ETD) and the amines as previously described [35]. Briefly, spermidine and
ETD at a molar ratio of 1:4 were added into a 2 mL glass vial, then the mixture was stirred at 90 ◦C
and protected from light for 2 days. The product was purified by silica gel column chromatography
with a gradient elution from CH2Cl2 to 75:22:3 CH2Cl2/MeOH/NH4OH. The transparent, pale yellow,
oily product was stored at −20 ◦C.
DSPE-PEG/lipidoid/cholesterol nanoparticles were prepared via the nanoprecipitation method
and purified by centrifugation [36]. Briefly, the synthesized lipidoid, cholesterol, and DSPE-PEG were
dissolved in 100% ethanol at concentrations of 100, 25 and 100 mg/mL, respectively, and combined at
a weight ratio of 2:2:1. The mixture was then injected quickly into acetate buffer (200 mM, pH 5.4)
while stirring to form empty nanoparticles. The DSPE-PEG/lipidoid/cholesterol-siRNA complexes
(briefly, lipidoid-siRNA complexes) were formed by mixing 10 pmol of siRNA (for a 50 nM siRNA
dose) with the empty nanoparticles in nuclease-free water at an RNA to nanoparticle ratio of 1 µg to
7.5 µL. After gentle mixing with a pipette, the solutions were incubated for 20 min at room temperature.
The lipidoid-siRNA complexes were used immediately.
2.2.4. Commercial Carriers
Lipofectamine 2000 (Thermo Fisher Scientific, Walthan, MA, USA), DharmaFECT 4 (Dharmacon,
Horizon Discovery, Cambridge, UK), and Metafectene PRO (Biontex, Munich, Germany) were used
as positive controls according to the manufacturers’ instructions. The weight (µg) RNA to volume
(µL) carrier ratio was 1:3.3 for Lipofectamine 2000 (L2000), 1:3 for DharmaFECT 4 (DF4), and 1:5 for
Metafectene PRO (PRO). After gentle mixing with a pipette, the solutions were incubated for 20 min
at room temperature to allow the formation of nanoparticles. The commercial complexes were
used immediately.
2.3. Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA)
The hydrodynamic diameter of the siRNA complexes was determined by DLS, using a Zetasizer
APS (Malvern Panalytical, Spectris plc, Egham, Surrey, UK) with a nominal 5 mV He-Ne laser operating
at a 633 nm wavelength. The refractive index of the lipid-based carriers and polymer-based carriers
was 1.33 and 1.450, respectively, and the viscosity was 0.8872 cP at 25 ◦C. For each sample, three
separate measurements were conducted with 20 runs each. The size of the lipidoid and commercial
complexes was analyzed by NTA using a NanoSight LM10 system (Malvern Panalytical, Spectris plc,
Egham, Surrey, UK) fitted with a high-sensitivity cCMOS camera and a 405 nm laser. Each sample was
appropriately diluted in PBS before the measurement. Videos of 60 s were recorded and analyzed with
the NTA software (version 3.1, build 3.1.45). The concentration ranges of the particles were between
108 and 109 particles per mL. Three measurements per sample were taken.
2.4. Retinal Pigment Epithelium (RPE) Cell Cultures
2.4.1. Human Retinal Pigment Epithelial Cells (ARPE-19)
ARPE-19 cells from ATCC (Manassas, VA, USA) were cultured in a growth medium composed
of Dulbecco’s modified Eagle’s medium/Nutrient Mixture F12, supplemented with 10% fetal bovine
serum (FBS), 2 mM of L-glutamine, 50 U/mL of streptomycin, and 50 U/mL of penicillin. The cells were
maintained at +37 ◦C in 7% CO2, sub-cultured (1:3 or 1:5) once a week, and the medium was renewed
once a week. The ARPE-19 cells were differentiated, as previously described, on laminin-coated Costar
Transwell inserts (pore size 0.4 µm, Corning, NY, USA) at a seeding density of 160,000 cells/cm2 [34].
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The growth medium was renewed twice a week. The composition of the growth medium was the
same as above, except the FBS concentration was 1%. The cells were grown on inserts for 3–4 weeks.
The tight junction formation was evaluated by a transepithelial electrical resistance measurement
(TEER).
2.4.2. Primary Porcine RPE (pRPE)
Fresh porcine eyes were obtained from a local slaughterhouse (Jensens Slagtehus, Hadsten,
Denmark). The porcine eyes were kept on ice during transport and handled immediately upon arrival
to the laboratory. The extraocular tissues were removed with curved iris scissors. The anterior part
of the eye, the lens and the vitreous, were gently removed. The eye cup was placed in a well plate
and filled with PBS. After 10 min, the PBS was removed, together with the neural retina. The eye
cup was then filled with 0.25% trypsin-EDTA and placed in the incubator at +37 ◦C for 30 min. After
this time, the detached RPE cells were collected. The RPE cells of 20 eyes were collected in 50 mL
tubes containing 1 part trypsin-EDTA with the cells and 2 parts cell culture medium (low glucose
DMEM supplemented with pyruvate, 10% FBS, 2 mM GlutaMAX, and 1% penicillin-streptomycin
(10,000 U/mL)). The tubes were centrifuged three times at 1000 rpm for 2 min, and each time the
supernatant was replaced by fresh culture medium. Then, the cells were placed in a T25 tissue culture
flask and the medium was replaced twice a week until the cell monolayer reached confluency. The
pRPE cells were then seeded on collagen IV-coated (11.2 µg collagen/insert) Transwell inserts (12 well)
at a density of 160,000 cells/cm2 and cultured for 4 weeks. The cell culture medium had the same
composition as described above, except it contained only 1% FBS. The tight junction formation was
evaluated by a transepithelial electrical resistance measurement (TEER).
2.4.3. Human Embryonic Stem Cell-Derived RPE (hESC-RPE)
The pluripotent hESC line Regea15/025 (46,XX) was derived [37], characterized, and maintained
on inactivated human foreskin fibroblasts (hFF) (CRL-2429, ATCC, Manassas, VA, USA) in serum-free
hESC culture medium, as previously described [38]. The spontaneous differentiation of RPE from
pluripotent hESCs in floating aggregates using the RPEbasic differentiation method and subsequent
selection and enrichment were performed as previously described [38,39]. The hESC-RPE cells were
matured on Matrigel-coated inserts (13.44 µg Matrigel/insert, Millicell Hanging Inserts, MCRP24H48,
seeding density 75,000 cells/insert) for 2 and 4 weeks. The tight junction formation was evaluated by a
transepithelial electrical resistance measurement (TEER).
2.5. Transepithelial Electrical Resistance Measurement (TEER)
The TEER of the cell monolayers was measured with a Millicell ERS-2 Volt-Ohm Meter equipped
with a silver/silver chloride electrode (EMD Millipore Corporation, Billerica, MA, USA). Briefly,
the STX01 electrode was sanitized with 70% ethanol for 15 min immediately before use, then the
electrode was used to carry out the measurements. To obtain the actual monolayer resistance, the
resistance reading across a blank insert (insert without cells) was subtracted from the resistance reading
across the monolayer (insert with cells). The unit area resistance (Ω cm2) was calculated by multiplying
the resistance reading (Ω) with the effective surface area of the filter membrane (cm2).
2.6. Cytotoxicity
The cytotoxicity of the polyplexes, lipoplexes, and L2000/siRNA complexes was determined by
an MTT assay. The ARPE-19 cells were seeded on a 24-well plate at a density of 100,000 cells/well in
500 µL of supplemented growth medium. The next day, the cells were washed with PBS (1x, pH 7.2).
The formulations with 50 nM of siRNA were incubated with the cells in Opti-MEM for 5 h. Then, the
cells were washed with PBS and incubated for 4 h with 400 µL of 0.5 mg/mL thiazolyl blue tetrazolium
bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA). After incubation, formazan crystals of the living
cells were solubilized by adding 100 µL of 10% sodium dodecyl sulphate −0.1 M hydrochloric acid.
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On the following day, the formazan amount was quantified by measuring the absorbance at 570 nm
(Varioskan Flash, Thermo Fisher Scientific, Waltham, MA, USA). The cell viability was calculated as a
percentage of the non-treated cells.
The proliferation of the cells transfected with the lipidoid and DF4 complexes was measured
by an alamarBlue assay following the instructions given by the manufacturer. This assay was used
with differentiated cells, because it did not require cell lysis. Briefly, an amount equal to 10% of cell
culture volume (50 µL) of alamarBlue reagent was added apically and the cells were returned to the
incubator for one hour. Thereafter, 100 µL of cell culture medium was transferred to a black well plate,
and the fluorescence was measured at λex 560 nm and λem 590 nm with a plate reader (Varioskan Flash,
Thermo Fisher Scientific, Waltham, MA, USA). The cell proliferation was calculated relative to the
non-treated cells.
2.7. Gene Silencing
2.7.1. Interleukin 6 (IL-6) Protein Knockdown
Dividing cells: The ARPE-19 cells were seeded on a 24-well plate at a density of 100,000 cells/well
in 500 µL of supplemented growth medium. Next day, the cells were transfected with 50 nM of IL-6
siRNA in Opti-MEM for 5 h. After transfection, the cells were washed with PBS, and 1 mL of growth
medium containing 10 µg/mL of lipopolysaccharide (LPS, Escherichia coli O55:B5 Sigma-Aldrich,
St. Louis, MO, USA) was added to the cells. The LPS was used to induce IL-6 secretion [40]. Samples of
500 µL were collected from the supernatant 72 h after the polyplex and lipoplex removal and replaced
with the equal volume of LPS medium. The amount of IL-6 was analyzed from the collected medium
samples using a human IL-6 ELISA kit according to the instructions provided by the manufacturer
(Gen-Probe, Diaclone SAS, Besançon, France). The relative IL-6 protein secretion was calculated by
comparing the exposed cells to the LPS-treated cells without any exposure (100%).
Differentiated cells: The ARPE-19 cells cultured for 3–4 weeks were transfected apically with
100 nM of IL-6 siRNA in Opti-MEM for 5 h. After incubation, the medium was removed and the cells
were washed with PBS. Growth medium supplemented with 10 µg/mL of LPS was added to the apical
and basolateral sides of the cells. Medium samples were collected at 2, 5, and 9 days. The removed
samples were replaced with an equal volume of the LPS medium. The samples were analyzed with the
human ELISA kit described above.
2.7.2. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and Hypoxanthine
Phosphoribosyltransferase 1 (HPRT1) MRNA Knockdown
The differentiated cells were transfected apically with 10, 50, or 100 nM of GAPDH siRNA (ARPE-19
and hESC-RPE) or HPRT1 siRNA (pRPE) overnight in full medium, including serum. Two days
after transfection, the total RNA was isolated using the NucleoZOL reagent (Macherey-Nagel, Düren,
Germany). The total RNA concentration was determined with a DeNovix DS-11 spectrophotometer
(DeNovix Inc., Wilmington, DE, USA). The cDNA was synthesized using the RevertAid First strand
cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA). The quantification of the GAPDH
mRNA, HPRT1 mRNA, and β-actin mRNA was performed with the LightCycler 480 SYBR Green I
Master (Roche, Basel, Switzerland). The primer concentration was 250 nM, and 4 ng of cDNA was used
in the final 10 µL reaction volume. All the quantitative PCRs were performed on a LightCycler® 480
Instrument (Roche, Basel, Switzerland). The sequence-specific amplification of cDNAs was verified by
performing a melting-point analysis. For the differentiated ARPE-19 and hESC-RPE cells, the GAPDH
mRNA expression was normalized to the endogenous β-actin, whereas for the pRPE cells, the HPRT1
mRNA expression was normalized to the endogenous GAPDH.
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2.8. Cell Uptake
The cells were transfected as in paragraph 2.7 using either FAM-IL-6 siRNA or Alexa Fluor
488 dsDNA (21-mer). After incubation, the cells were washed three times with Hanks’ Balanced
Salt Solution (HBSS) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10 mM of
HEPES (pH 7.4). Then, the cells were detached with trypsin, re-suspended in the HBSS-HEPES
buffer, and centrifuged at 1200 rpm for 10 min. The cells were analyzed by flow cytometry (LSR II,
Becton, Dickinson and Company, Franklin Lakes, NJ, USA and Gallios, Beckman Coulter Life Sciences,
Indianapolis, IN, USA). The data collection and analysis were controlled by the FACSDiva software
(BD Biosciences) and Kaluza software (Beckman Coulter Life Sciences), where 10,000 cell events were
collected for each sample. Non-treated and naked FAM-IL-6 siRNA-treated cells were used for setting
the baseline and for calculating the relative cell association of the siRNA formulations.
2.9. Intracellular Distribution
The intracellular distribution of Atto565 dsDNA (21-mer) was observed with confocal microscopy.
The hESC-RPE cells were transfected as in paragraph 2.7. The lysosomes were labeled with the CellLight
Lysosomes-GFP reagent (Thermo Fisher Scientific, Waltham, MA, USA) following the instructions
given by the manufacturer. Briefly, 24 h after transfection, the CellLight reagent (16 µL) was added
and incubated with the cells for ≥ 16 h. Thereafter, the cells were fixed with 4% paraformaldehyde for
10 min at room temperature and mounted in Vectashield mounting medium (Vector Laboratories Inc.,
Burlingame, CA, USA). The melanosomes were labeled by immunocytochemistry as the following.
The cells were fixed with 4% paraformaldehyde for 10 min at room temperature, followed by
permeabilization with 0.5% saponin in PBS for 10 min and blocking with 1% bovine serum albumin
(BSA), 22.52 mg/mL glycine in PBST (PBS +0.1% Tween 20) for 30 min. The cells were then incubated
with the primary polyclonal antibody Rab27a (1:200, Sicgen, Cantanhede, Portugal) in 1% BSA in PBST
in a humidified chamber for 1 h at room temperature, followed by incubation with the secondary
antibody (donkey anti-goat Alexa Fluor 488, 1:500, Thermo Fisher Scientific, Waltham, MA, USA) in 1%
BSA in PBST for 1 h at room temperature. The cell nuclei were stained with the DAPI included in the
Vectashield mounting medium. Images were captured on an Olympus IX-83 fluorescent microscope
with the Andor confocal spinning unit and Andor iXon Ultra 897 camera, Olympus Upsalo W, 60x/1.20
NA water objective lens, using the Olympus cellSens software (Olympus). Multichannel images were
processed using the Fiji software (ImageJ 1.52s).
2.10. Statistical Analysis
A one-way ANOVA followed by Tukey’s multiple comparisons test was performed using
GraphPad Prism version 8.4.2 for macOS (GraphPad Software, San Diego, CA, USA). The significance
level of the test was set to 0.05.
3. Results
3.1. Particle Size and Polydispersity Index (PdI)
The particle size and polydispersity index (PdI) of the siRNA/carrier complexes, evaluated by
DLS and NTA, are summarized in Table 1. The PBE30-b-PK30 polyplexes were around 50 nm and had a
narrow size distribution, whereas the DOTAP/DOPE/PS lipoplexes were about 200 nm in diameter
and displayed a higher polydispersity. The lipidoid-siRNA complexes (lipidoid) were approximately
150 nm in diameter and had a monodisperse distribution. Comparable results were obtained when
their sizes were measured with NTA. The commercial complexes were measured by NTA, since the
phenol red present in the nanoparticle preparation medium disturbed the DLS measurement. The
commercial complexes sizes were 160–280 nm and polydisperse.
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Table 1. Size and polydispersity index of siRNA/carrier complexes measured by dynamic light
scattering (DLS), and size measured by nanoparticle tracking analysis (NTA).
Carrier Size, DLS (nm) PdI Size, NTA (nm)
Polyplex 46.4 ± 14 0.20 n/a
Lipoplex 216 ± 27 0.40 ± 0.05 n/a
Lipidoid 166 ± 18 0.21 ± 0.03 191 ± 62
DharmaFect 4 n/a n/a 281 ± 160
Metafectene PRO n/a n/a 160 ± 88
Lipofectamine 2000 n/a n/a n/a
3.2. Cytotoxicity
The in vitro toxicity of all the siRNA/carrier complexes was low, and the RPE cells maintained an
over 80% viability after treatment (Figure 1).
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at a siRNA dose of 50 nM. Cell viability was evaluated by MTT (in dividing cells) and an alamarBlue
assay (in differentiated cells) after 5 h of exposure to the complexes, and is presented as the percentage
of untreated cells. Data are presented as mean + SD, n = 3.
3.3. Knockdown Efficacy in RPE Cell Models
3.3.1. Human ARPE-19
Dividing ARPE-19 e ls: The IL-6 protein knockd wn was about 70% (p < 0.0001) with the
lipoplexes (Figure 2), whereas no knockdown was measured with the polyplexes, even after treatment
with chloroquine, a commonly used lysosomotropic agent that promotes endosomal escape and
enhances transfe tion [41] (Supplementary Figure S1). L2000 resulted in a 60% (p = 0.0003) decrease in
protein secretion. There was no statistically significant difference between the knockdown efficacy of
the lipoplexes and L2000 (p = 0.4663). The negative control siRNA did not promote silencing.
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Figure 2. IL-6 knockdown in ividing ARPE-19 cells, 3 days after transfection. Black columns indicate
the IL-6 siRNA (50 nM), the white columns i dicate the negativ control siRNA (50 nM). IL-6 protein
secretion was evaluated with ELISA and was normalized to LPS-treated cells (100%, column with
diagonal pattern). The basal IL-6 secretio of dividing ARPE-19 cells was 5% relative o the LPS-treated
cells. L2000: Lipofec amine 2000; ctrl: negative control siRNA; * indicates statistical ignificance
(p < 0.05). Data are presented as mean + SD, n = 3–4.
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Differentiated ARPE-19 cells: The IL-6 protein knockdown was highest with the lipoplexes,
at about 60% (p < 0.0001) 5 days after transfection (Figure 3), whereas the L2000 resulted in a 40%
(p = 0.0207) decrease in protein secretion at the same time point. The knockdown efficacy between the
lipoplexes and L2000 at day 5 was not statistically significant (p = 0.5235). Interestingly, the silencing
effect of lipoplexes was delayed compared to L2000, and prolonged to at least 9 days after transfection
(p < 0.0001). The polyplexes were not tested with the differentiated ARPE-19 cells, since no knockdown
was detected in the dividing cells. The negative control siRNA did not promote silencing. The siRNA
dose was doubled (100 nM) in the differentiated cells, because no knockdown could be measured with
the same dose used in the dividing cells (50 nM). The TEER of the ARPE-19 cells was 39 ± 5 Ω cm2.
Figure 3 illustrates the decrease in IL-6 secretion on the apical side of the monolayer; the basolateral
IL-6 secretion was also measured with similar results (data not shown).
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Figure 3. Apical IL-6 protein knockdown in diffe ted ARPE-19 cells, 2 (a), 5 (b), and 9 (c) days
after transfection. Black olumns indicate the I - (1 0 nM), the white colum s indicate the
negative control siRNA (100 nM). IL-6 protein secretion was evaluated ith ELISA and normalized to
the LPS-treated cells (100%, column with diagonal pattern). L2000: Lipofectamine 2000; ctrl: negative
control siRNA; * indicates statistical significance (p < 0.05). Data are presented as mean + SD, n = 3–6.
The lipidoid-siRNA complexes-mediated GAPDH mRNA silencing in differentiated ARPE-19
cells (Figure 4) was achieved with the same 50 nM dose used in the dividing cells. After transfection,
the GAPDH gene expression was decreased by 60% (p = 0.0019). The DF4-mediated silencing was
approximately 90% (p < 0.0001), however there was no statistical significance between the lipidoids
and DF4 (p = 0.1530). The lipidoids retained a 64 silencing efficacy ven at a low 10 nM siRNA
dose (data not shown). The negative control si i ot promote silencing. The TEER of the
ARPE-19 cells in this exp riment was 78 ± 13 Ω c .
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Figure 4. GAPDH mRNA knockdown in differentiated ARPE-19 cells, 2 days after transfection. Black
columns indicate the GAPDH siRNA (50 nM), the hite columns indicate the negative control siRNA
(50 nM). GAPDH mRNA expression was evaluate i qPCR and normalized to the endogenous
β-actin. Results are present d as the % of remai i e expre sion. UT: untr ated c ntrol cells; DF4:
DharmaFect 4; ctrl: negative control siRNA; * indi t s statistical significance (p < 0.05). Data are
present d as mean + SD, n = 3–5.
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3.3.2. Primary Porcine RPE (pRPE)
A siRNA dose of 50 nM was sufficient to silence the housekeeping gene HPRT1 in differentiated
pRPE cells with lipidoids (Figure 5). After transfection, the remaining HPRT1 gene expression was
45% (p = 0.0294). The DF4 achieved a 50% knockdown (p = 0.0482). The negative control siRNA did
not promote silencing. The TEER of the pRPE cells was 853 ± 39 Ω cm2.
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Figure 5. HPRT1 mRNA knockdown in the differentiated primary pRPE cells, 2 days after transfection.
Black columns indicate the HPRT1 siRNA (50 nM), the white columns indicate the negative control
siRNA (50 nM). HPRT1 mRNA expression was evaluated with a qPCR and normalized to the
endogenous GAPDH. Results are presented as the % of remaining gene expression. UT: untreated
control cells; DF4: DharmaFect 4; ctrl: negative control siRNA; * indicates statistical significance
(p < 0.05). Data are presented as mean + SD, n = 3.
3.3.3. Human Embryonic Stem Cell-derived RPE (hESC-RPE)
A siRNA dose of 50 nM in lipidoids silenced the GAPDH by 50% (p = 0.0004) in 2-week matured
hESC-RPE cells (Figure 6a). The best carrier was PRO, with a knockdown efficiency of 75% (p < 0.0001),
while the efficiency of the other commercial carrier DF4 was 55% (p < 0.0001). The negative control
siRNA did not promote statistically significant silencing for PRO and lipidoids. The TEER of the
2-week matured hESC-RPE cells was 18 ± 5 Ω cm2.
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Figure 6. GAPDH mRNA knockdown in (a) 2-week and (b) 4-week matured hESC-RPE cells, 2 days
after transfection. Black columns indicate the GAPDH siRNA (50 nM), the white columns indicate
the negative control siRNA (50 nM). GAPDH mRNA expressio was evaluated with a qPCR and
normalized to the endogenous β-actin. Results are pr sented as the % of remaining gene expression.
UT: untreated control cells; DF4: DharmaFect 4; PRO: Metafectene PRO; ctrl: negative control siRNA;
* indicates statistical significance (p < 0.05). Data are presented as mean + SD, n = 3. Cell pigmentation
is visible in 4-week atured hESC-RPE.
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Despite the promising results obtained with the 2-week matured hESC-RPE cells, no statistically
significant knockdown was achieved in the 4-week matured cells (Figure 6b). The negative control
siRNA did not promote silencing. The TEER of the 4-week matured hESC-RPE cells was 435 ± 47 Ω cm2.
The 2-week matured cells were not pigmented, whereas pigmentation is clearly visible in the 4-week
matured cells.
3.4. Cell Uptake
Cell uptake studies were performed in order to evaluate the effect of cell differentiation on the
endocytosis of siRNA complexes. The carriers tested in the dividing ARPE-19 cells (polyplexes,
lipoplexes, and commercial carriers) all had a 100% cell association (measured as the % of positive cells,
Figure 7a). In the differentiated ARPE-19 and 4-week matured hESC-RPE cells instead, the lipidoids had
the highest % of positive cells (>90% in hESC-RPE, Figure 7b), while the lipoplexes had 20% positive
ARPE-19 cells. The L2000 and DF4 had 20% (ARPE-19) and 40% (hESC-RPE) positive cells, respectively.
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Figure 7. Percentage of positive (a) dividing ARPE-19 cells, and (b) differentiated RPE cells measured
by flow cytometry upon 5 h of treatment with fluorescent siRNA/dsDNA incorporated into different
carriers. Dividing ARPE-19 cells were transfected with 50 nM of FAM-IL-6 siRNA, the differentiated
ARPE-19 with 100 nM of FAM-IL-6 siRNA, and the 4-week matured hESC-RPE with 50 nM of Alexa
Fluor 488 dsDNA (21-mer). L2000: Lipofectamine 2000; DF4: DharmaFect 4. Data are presented as
mean + SD, n = 3.
3.5. Intracellular Distribution in hESC-RPE
The intracellular distribution of the fluorescently labelled dsDNA (used as a non-biologically
active mimic for siRNA) was studied in order to explain the striking knockdown differences observed
in the hESC-RPE that were matured for 2 and 4 weeks (Figure 6a,b).
3.5.1. 2-Week Matured hESC-RPE
The intracellular distribution of the fluorescently labelled dsDNA (used as a non-biologically
active mimic for siRNA, in red) was depend nt on the type of carrier. For DF4 (Figure 8a) nd
especially for PRO (Figure 8b), cytosolic staining (arrow ads), which may indicate endosomal release,
was observed. With these carriers, the labelled dsDNA also localized inside large aggregat s (arr ws).
In the case of lipidoids (Figur 8c), the dsDNA was found inside discrete, small v sicles, which did
not colocalize with lysosomes (in green). The Z-stack images indicate that for all the tested carriers,
dsDNA was found inside the cells.
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4. Discussion 
The pathogenesis of several age-related ocular disorders is characterized by the presence of 
continuous, low-grade inflammation. Silencing pro-inflammatory genes by siRNA is an attractive 
therapeutic option to reduce inflammation and restore homeostasis in the retina. Despite the 
undeniable potential of siRNA therapeutics, a key obstacle still hampering their widespread use is 
Figure 8. Intracellular distribution of ATTO565-labelled dsDNA (in red) in the 2-week matured
hESC-RPE. dsDNA (50 nM) was incorporated into the commercial carriers DF4 (a) and Metafectene
PRO (b), and into lipidoids (c). Lysosomes were labelled with CellLight Lysosomes-GFP (in green).
Cell nuclei (in blue) were labelled with DAPI. A: apical side; B: basolateral side. Scale bar: 10 µm.
3.5.2. 4-Week Matured hESC-RPE
PRO did not distribute evenly in the cytoplasm as in the 2-week matured cells (Figure 8b); rather,
it accumulated inside fairly large apical vesicles (Figure 9a and Supplementary video). The lipidoids
localized on the apical cell membrane (Figure 9b and Supplementary video) but were not found inside
cells. Subsequent staining with melanosomal marker Rab27a revealed that PRO was localized inside
melanosomes (Figure 9c–e) on the apical side of the cell monolayer.
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Figure 9. Intracellular distribution of ATTO565-labelled dsDNA (in red) in 4-week matured hESC-RPE.
dsDNA (50 nM) was incorporated into the commercial carrier Metafectene PRO (a) and into the
lipidoids (b). (c–e) Intracellular distribution of Metafectene PRO/dsDNA (50 nM) complexes in 4-week
matured hESC-RPE. (c) Melanosomes were identified with Rab27a antibody; (d) ATTO565-labelled
dsDNA; and (e) overlay image where melanosomes are in green, dsDNA in red, and cell nuclei in blue
(DAPI). A: apical side; B: basolateral side. Scale bar: 10 µm.
4. Discussion
The pathogenesis of several age-related ocular disorders is characterized by the presence of
continuous, low-grade inflammation. Silencing pro-inflammatory genes by siRNA is an attractive
therapeutic option to reduce inflammation and restore homeostasis in the retina. Despite the undeniable
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potential of siRNA therapeutics, a key obstacle still hampering their widespread use is the safe and
efficient delivery to target cells. Gene silencing in the RPE requires a carrier that can successfully deliver
the siRNA to a quiescent, terminally differentiated cell monolayer. siRNA therapeutics must first of all
gain access into cells, a process which occurs via endocytosis and whose mechanisms have been widely
studied. It is worth keeping in mind, however, that most of our current knowledge on endocytic
mechanisms is derived from studies of proliferating cells, and that the mechanisms prevailing in
non-dividing cells might be quite different [42]. Several studies have shown, for example, that cell
differentiation causes a reduction in the uptake of different cargoes in intestinal [43–45], kidney [46],
and airway [47] epithelial cells. While we could not find any published literature on the effect of
cell differentiation on the endocytic activity of RPE cells, we also observed a decreased uptake of
siRNA complexes in differentiated ARPE-19 cells compared to dividing cells. While lipidoid-siRNA
complexes did retain a > 90% cell association in 4-week matured hESC-RPE cells, a confocal microscope
analysis revealed that they were not internalized inside cells, but instead they localized apically at the
cell surface. Thus, our results indicate that, similarly to other epithelial tissues [43–47], differentiation
alters the endocytic activity of RPE cells and causes a decrease in the uptake of siRNA complexes.
RPE cell differentiation also lessened the efficacy of gene silencing. While clearly a less efficient
cell uptake may partly explain the decreased knockdown, an additional important barrier for efficient
siRNA therapy was revealed to be the sequestration of dsDNA (used as siRNA mimic) by melanosomes.
Melanosomes do not normally occur in ARPE-19 cells [48] and 2-week matured hESC-RPE (Figure 6a),
whereas the 4-week matured hESC-RPE were heavily pigmented (Figure 6b). Some drugs have
long been known to be stored inside melanosomes via melanin binding. Indeed, the first reports
describing the accumulation of drugs inside ocular melanin were published more than 60 years
ago [49–51], and several thousands of compounds, mostly small molecular weight drugs, have
been investigated for melanin binding in vitro and in vivo since [52,53]. Very few studies, however,
describe the melanin binding of oligonucleotides and nanoparticles. Pitkänen and colleagues [54]
found that oligonucleotides did not bind to isolated and synthetic melanin, whereas Geng and
coworkers [55] showed that melanin from bacteria interacted with DNA. Despite these conflicting
results, the entrapment of siRNA complexes inside melanosomes may not require melanin binding.
Schraermeyer and colleagues, for example, observed the accumulation of gold nanoparticles (10–20
nm) used to label rod outer segments [56] and latex particles (100 nm) [57] in the narrow space
between melanin and the melanosome membrane in the RPE of bovine RPE-choroid tissue explants.
Melanosomes, whose membranes and contents are largely derived from endosomes, are members
of the lysosome-related organelle (LRO) family [58]. Previous work has found that, while the vast
majority of siRNA lipoplexes that enter cells end up in endolysosomes, only a few percent of siRNA
reach the cytosol, either by direct fusion between the lipoplexes and the plasma membrane [59] or via
endosomal escape [60,61]. Accordingly, only a fraction of the siRNA dose that localizes in the cytosol
is responsible for the gene silencing effect. In our study, we observed the significant cytoplasmic
distribution of siRNA in 2-week matured hESC-RPE (Figure 8b). In addition, none of the different
complexes co-localized with lysosomes. Upon cell pigmentation at 4 weeks, however, the cytoplasmic
staining disappeared, and, in the case of Metafectene PRO, the siRNA localized inside melanosomes
instead. This also corresponded to a loss in gene silencing. It is possible that if, upon delivery to
the melanosomes, the siRNA is still incorporated into lipoplexes, then the cationic lipoplexes may
bind to the polyanionic melanin [53]. This binding may prevent the interaction of lipoplexes with the
melanosomal membrane, and thus preclude the release of siRNA into the cytosol.
In summary, our study highlights the importance of picking a physiologically relevant RPE cell
model for the selection of siRNA delivery systems. While it is tempting to evaluate their efficacy only
in dividing, non-pigmented RPE cells, there is a real risk that these systems will not work in vivo.
Given their easy culture, low costs, and quick growth, dividing ARPE-19 cells are still valuable in the
early selection rounds and when large preliminary screens are performed. Nevertheless, advanced
selections should be carried out with RPE models that better mimic the outer blood-retina barrier—that
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is, differentiated, pigmented RPE cells. This simple but important choice may lead to a more stringent
selection of delivery systems and increase their chance of success in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/7/667/s1.
Figure S1: IL-6 knockdown in dividing ARPE-19 cells, 3 days after transfection. Video S1: PRO.avi. Video S2:
Lipidoid.avi.
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